Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Day One Biopharmaceuticals (DAWN) Operating Expenses (2023 - 2025)

Historic Operating Expenses for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Q3 2025 value amounting to $64.0 million.

  • Day One Biopharmaceuticals' Operating Expenses fell 12.32% to $64.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $299.3 million, marking a year-over-year decrease of 450.28%. This contributed to the annual value of $348.4 million for FY2024, which is 6908.87% up from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Operating Expenses is $64.0 million, which was down 12.32% from $68.9 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Operating Expenses' 5-year high stood at $123.0 million during Q2 2024, with a 5-year trough of $49.3 million in Q2 2023.
  • In the last 3 years, Day One Biopharmaceuticals' Operating Expenses had a median value of $65.4 million in 2024 and averaged $71.3 million.
  • In the last 5 years, Day One Biopharmaceuticals' Operating Expenses skyrocketed by 14972.39% in 2024 and then tumbled by 4399.79% in 2025.
  • Quarter analysis of 3 years shows Day One Biopharmaceuticals' Operating Expenses stood at $59.5 million in 2023, then surged by 58.85% to $94.5 million in 2024, then plummeted by 32.26% to $64.0 million in 2025.
  • Its Operating Expenses stands at $64.0 million for Q3 2025, versus $68.9 million for Q2 2025 and $71.8 million for Q1 2025.